Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dendreon Crosses Fingers, Knocks on Wood, And Resubmits Provenge To FDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Dendreon resubmitted its prostate cancer treatment Provenge (sipuleucel-T) to FDA Nov. 2, two and a half years after the agency disagreed with an advisory panel and rejected the vaccine, which targets metastatic, castration-resistant forms of the disease.

You may also be interested in...

Dendreon Raises $230 Million To Fund Filing And Anticipated Launch Of Provenge

With strong overall survival data in hand for its prostate cancer vaccine, Seattle biotech takes advantage of increased investor interest.

Dendreon’s Therapeutic Vaccine Provenge Gets “Complete Response” From FDA

FDA is requesting additional clinical data to support the efficacy of Dendreon’s BLA.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts